Blood Chromogranin A is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary NET/NET.
Identification of circulating tumor markers for clinical management in bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable clinical interest. Chromogranin A (CgA), a "universal" NET biomarker, is considered controversial as a circulating biomarker of BPNEN. Assess utility of CgA in the diagnosis and management of BPNEN in a multicentric study. CgA diagnostic metrics were assessed in lung NET/NENs (n=200) and controls (n=140), randomly assigned to a Training and Test set (100 BPC and 70 controls in each). Assay specificity was evaluated in neoplastic lung disease (n=137) and non-neoplastic lung disease (n=77). CgA efficacy in predicting clinical status was evaluated in the combined set of 200 NET/NENs. CgA levels in BPNET subtypes (AC vs TC) and grade was examined. The clinical utility of an alteration of CgA levels (±25%) was evaluated in a subset of 49 BPNET over 12-months. CgA measurement was by NEOLISATM kit (EuroDiagnostica). Sensitivity and specificity in the training set was 41%/98% respectively. Test set data was 42%/87%. Training set area under receiver operator characteristic (AUROC) analysis differentiated BPC from control area under the curve (AUC): 0.61±0.05 p=0.015. Test set the data were AUC: 0.58±0.05, p=0.076. In the combined set (n=200), 67% BPNET/NEN (n=134) had normal CgA levels. CgA levels did not distinguish histological subtypes (TC vs. AC, AUC: 0.56±0.04, p=0.21), grade (p=0.45-0.72) or progressive from stable disease (AUC: 0.53±0.05 p=0.47). There was no correlation of CgA with Ki-67 index (Pearson r=0.143, p=0.14). For non-neoplastic diseases (COPD and IPF), CgA was elevated in 26-37%. For neoplastic disease (NSCLC, SCC), CgA was elevated in 11-16%. The neuroendocrine SCLC also exhibited elevated CgA (50%). Elevated CgA was not useful for differentiating BPNET/NEN from these other pathologies. Monitoring BPNET/NEN over a 12-month period identified neither CgA levels per se nor changes in CgA was reflective of somatostatin analog treatment outcome/efficacy or the natural history of the disease (progression). Blood CgA levels are not clinically useful as a biomarker for lung BPNET/NEN The low specificity and elevations in both non-neoplastic as well as other common neoplastic lung diseases identified limited clinical utility for this biomarker.